High‐dose transdermal nicotine in Parkinson's disease patients: a randomized, open‐label, blinded‐endpoint evaluation phase 2 study

Abstract

High doses of transdermal nicotine were tolerated, but our study failed to demonstrate significant improvement in UPDRS motor scores. Improvement in unblinded secondary outcomes (UPDRS-II, UPDRS-IV, doses of l-DOPA equivalents) suggest a possible benefit for patients treated with nicotine, which should be confirmed in larger double blind, placebo-controlled studies.